Successful treatment of a 3‐year‐old girl with generalized pustular psoriasis using secukinumab monotherapy

Zhu, Huiying; Song, Pingping; Du, Donghong; Tian, Haijun

doi:10.1111/pde.14795

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another 9 case reports suggest the effectiveness and safety of secukinumab in GPP management. 107–111 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna¹,

Camela²,

Ruggiero³

et al. 2023

CCID

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a potentially life-threatening condition, characterized by recurring episodes or flares of widespread cutaneous erythema with macroscopic sterile pustules. An irregular innate immune response is linked to GPP, which is considered an auto-inflammatory disorder, while innate and adaptive immunopathogenic responses are involved in psoriasis pathogenesis. In consequence, different cytokine cascades have been suggested to be mainly involved in the pathogenesis of each different psoriasis form, with the interleukin (IL)23/IL17 axis implied in plaque psoriasis, and the IL36 pathway in the GPP. As regards GPP treatment, conventional systemic drugs available for plaque psoriasis are usually used as the first-line treatment option. However, contraindications and adverse events often limit the use of these therapies. In this scenario, biologic drugs may represent a promising treatment option. To date, even if 12 different biologics have been approved for plaque psoriasis, none of these is approved for GPP where they are employed off-label. Recently, spesolimab, an anti-IL36 receptor monoclonal antibody, has been recently approved for GPP. The purpose of this article is to assess the current literature about the use of biological therapies for the treatment of GPP to establish the basis for a shared GPP management algorithm.

show abstract

“…Another 9 case reports suggest the effectiveness and safety of secukinumab in GPP management. 107–111 …”

Section: Resultsmentioning

confidence: 99%

“…106 Another 9 case reports suggest the effectiveness and safety of secukinumab in GPP management. [107][108][109][110][111] Finally, two cases of paradoxical GPP induced by secukinumab have been reported. 112,113…”

Section: Secukinumabmentioning

confidence: 97%

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna¹,

Camela²,

Ruggiero³

et al. 2023

CCID

View full text Add to dashboard Cite

show abstract

“…Secukinumab is a fully human immunoglobulin‐Gκ IL‐17A monoclonal antibody and decreases IL36R activation by inhibiting IL‐17A and disturbing the inflammatory loop of GPP. Several cases and case series have described the efficacy and safety of secukinumab 19,57–66 . Our team reviewed the efficacy and adverse events of secukinumab in 20 Chinese pediatric patients with GPP, with the ages ranging from 6 to 12 years and the age of onset ranging from 2 months to 11 years 19 .…”

Section: Systemic Treatmentsmentioning

confidence: 99%

“…Several cases and case series have described the efficacy and safety of secukinumab. 19 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 Our team reviewed the efficacy and adverse events of secukinumab in 20 Chinese pediatric patients with GPP, with the ages ranging from 6 to 12 years and the age of onset ranging from 2 months to 11 years. 19 All the children had improvement in symptoms in the first week, and all patients achieved a JDA severity index of 0/1 in 3 weeks.…”

Section: Systemic Treatmentsmentioning

confidence: 99%

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Chen,

Xiang,

Wang

et al. 2023

Pediatric Investigation

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe subtype of psoriasis, commonly combined with systemic inflammation. Gene mutations have been found to be associated with GPP and vary by ethnicity. Systemic treatments are usually required for the severity and potential complications of GPP. However, there is no common consensus in China, especially among pediatric patients, whose data are scarce. Acitretin, methotrexate, and cyclosporine are widely used in pediatrics with GPP, while the adverse effects should be highlighted. The emergence of different biological agents brings us into a new era. This article discusses the genetic background of Chinese patients and demonstrates the evidence of treatment in pediatrics with GPP.

show abstract

Acitretin

2022

Reactions Weekly

View full text Add to dashboard Cite

Successful treatment of a 3‐year‐old girl with generalized pustular psoriasis using secukinumab monotherapy

Cited by 6 publications

References 5 publications

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Acitretin

Contact Info

Product

Resources

About